what is microdosing glp-1 mean popular, but there's little evidence it works GLP-1 Microdosing Explained - Gift

Support from others on the same journey feeling better, together

UK NHS, Jan 3, 2024

My doctor was right, she said

requires careful consideration) Severe gastrointestinal disease (e.g., gastroparesis) Each patient is assessed individually to determine safety and appropriateness 6

Injectable Protocol (Systemic + Gut) For users who want systemic delivery alongside gut-targeted action: Loading Phase (Weeks 1 to 4): BPC-157: 250 to 500 mcg per day, subcutaneous injection (abdomen) KPV: 200 to 500 mcg per day, subcutaneous injection (abdomen) Maintenance Phase (Weeks 5 to 8): BPC-157: 250 mcg per day KPV: 200 to 300 mcg per day Extended Stack Options For enhanced regenerative effect beyond gut health, some practitioners add: TB-500: 2 to 2.5 mg twice weekly adds systemic cell migration and tissue remodeling for broader recovery GHK-Cu: 1 to 2 mg per day subcutaneous adds collagen production support and wound healing acceleration Timing and Administration Notes For oral gut-focused use, some users dose BPC-157 in the morning and KPV in the evening to maintain continuous coverage throughout the day

The label also states that Mounjaro is not recommended in patients with severe gastroparesis, and it includes warnings for acute kidney injury due to volume depletion in patients with reactions that may cause dehydration